KRT5 mutation regulate melanin metabolism through notch signalling pathway between keratinocytes and melanocytes
© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd..
Dowling-Degos disease (DDD) is an autosomal dominant hereditary skin disease characterized by acquired reticular hyperpigmentation in flexural sites, and one of its causative genes is KRT5 gene. But the effect of KRT5, expressed only in keratinocytes, on melanocytes is unclear. Other pathogenic genes of DDD include POFUT1, POGLUT1 and PSENEN genes, which is involved in posttranslational modification of Notch receptor. In this study, we aim to determine the ablation of keratinocyte KRT5 affect melanogenesis in melanocyte through Notch signalling pathway. Here we found that KRT5 downregulation decreased the expression of the Notch ligand in keratinocytes and Notch1 intracellular domain in melanocytes, by establishing two cell models of ablation of KRT5 in keratinocytes based on CRISPR/Cas9 site-directed mutation and lentivirus-mediated shRNA. Treatment of melanocytes with Notch inhibitors had same effects with ablation of KRT5 on increase of TYR and decrease of Fascin1. Activation of Notch signalling reverses the effect of ablation of KRT5 on melanogenesis. Immunohistochemistry of DDD lesions with KRT5 gene mutation confirmed changes in the expression of relevant molecules in Notch signalling. Our research elucidates molecular mechanism of KRT5-Notch signalling pathway in the regulation of melanocytes by keratinocytes, and preliminary reveal the mechanism of DDD pigment abnormality caused by KRT5 mutation. These findings identify potential therapeutic targets of the Notch signalling pathway for the treatment of skin pigment disorders.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Experimental dermatology - 32(2023), 6 vom: 21. Juni, Seite 752-765 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jia, Weixue [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 09.06.2023 Date Revised 11.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/exd.14761 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353159166 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353159166 | ||
| 003 | DE-627 | ||
| 005 | 20231226055353.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/exd.14761 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1177.xml |
| 035 | |a (DE-627)NLM353159166 | ||
| 035 | |a (NLM)36809573 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jia, Weixue |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a KRT5 mutation regulate melanin metabolism through notch signalling pathway between keratinocytes and melanocytes |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.06.2023 | ||
| 500 | |a Date Revised 11.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. | ||
| 520 | |a Dowling-Degos disease (DDD) is an autosomal dominant hereditary skin disease characterized by acquired reticular hyperpigmentation in flexural sites, and one of its causative genes is KRT5 gene. But the effect of KRT5, expressed only in keratinocytes, on melanocytes is unclear. Other pathogenic genes of DDD include POFUT1, POGLUT1 and PSENEN genes, which is involved in posttranslational modification of Notch receptor. In this study, we aim to determine the ablation of keratinocyte KRT5 affect melanogenesis in melanocyte through Notch signalling pathway. Here we found that KRT5 downregulation decreased the expression of the Notch ligand in keratinocytes and Notch1 intracellular domain in melanocytes, by establishing two cell models of ablation of KRT5 in keratinocytes based on CRISPR/Cas9 site-directed mutation and lentivirus-mediated shRNA. Treatment of melanocytes with Notch inhibitors had same effects with ablation of KRT5 on increase of TYR and decrease of Fascin1. Activation of Notch signalling reverses the effect of ablation of KRT5 on melanogenesis. Immunohistochemistry of DDD lesions with KRT5 gene mutation confirmed changes in the expression of relevant molecules in Notch signalling. Our research elucidates molecular mechanism of KRT5-Notch signalling pathway in the regulation of melanocytes by keratinocytes, and preliminary reveal the mechanism of DDD pigment abnormality caused by KRT5 mutation. These findings identify potential therapeutic targets of the Notch signalling pathway for the treatment of skin pigment disorders | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Dowling-Degos disease | |
| 650 | 4 | |a KRT5 | |
| 650 | 4 | |a melanin metabolism | |
| 650 | 4 | |a notch | |
| 650 | 4 | |a skin pigmentation disorder | |
| 650 | 7 | |a Melanins |2 NLM | |
| 650 | 7 | |a PSENEN protein, human |2 NLM | |
| 650 | 7 | |a Membrane Proteins |2 NLM | |
| 650 | 7 | |a Amyloid Precursor Protein Secretases |2 NLM | |
| 650 | 7 | |a EC 3.4.- |2 NLM | |
| 650 | 7 | |a KRT5 protein, human |2 NLM | |
| 650 | 7 | |a Keratin-5 |2 NLM | |
| 650 | 7 | |a POGLUT1 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.4.1.- |2 NLM | |
| 650 | 7 | |a Glucosyltransferases |2 NLM | |
| 650 | 7 | |a EC 2.4.1.- |2 NLM | |
| 700 | 1 | |a Zhang, Yuanyuan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xue |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Lingling |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Heng |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Yiqun |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jianbo |e verfasserin |4 aut | |
| 700 | 1 | |a Mao, Qiuxia |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Youming |e verfasserin |4 aut | |
| 700 | 1 | |a Kong, Lingzhuo |e verfasserin |4 aut | |
| 700 | 1 | |a Mo, Ran |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Chengrang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Experimental dermatology |d 1992 |g 32(2023), 6 vom: 21. Juni, Seite 752-765 |w (DE-627)NLM012660701 |x 1600-0625 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2023 |g number:6 |g day:21 |g month:06 |g pages:752-765 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/exd.14761 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2023 |e 6 |b 21 |c 06 |h 752-765 | ||